ARCT
Price
$6.26
Change
+$0.36 (+6.10%)
Updated
Nov 21 closing price
Capitalization
177.86M
Intraday BUY SELL Signals
BNTX
Price
$95.59
Change
-$1.38 (-1.42%)
Updated
Nov 21 closing price
Capitalization
22.99B
108 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ARCT vs BNTX

Header iconARCT vs BNTX Comparison
Open Charts ARCT vs BNTXBanner chart's image
Arcturus Therapeutics Holdings
Price$6.26
Change+$0.36 (+6.10%)
Volume$1.44M
Capitalization177.86M
BioNTech SE American Depositary Share
Price$95.59
Change-$1.38 (-1.42%)
Volume$1.31M
Capitalization22.99B
ARCT vs BNTX Comparison Chart in %
ARCT
Daily Signal:
Gain/Loss:
BNTX
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ARCT vs. BNTX commentary
Nov 22, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARCT is a Hold and BNTX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 22, 2025
Stock price -- (ARCT: $6.26 vs. BNTX: $95.59)
Brand notoriety: ARCT and BNTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARCT: 93% vs. BNTX: 165%
Market capitalization -- ARCT: $177.86M vs. BNTX: $22.99B
ARCT [@Biotechnology] is valued at $177.86M. BNTX’s [@Biotechnology] market capitalization is $22.99B. The market cap for tickers in the [@Biotechnology] industry ranges from $108.28B to $0. The average market capitalization across the [@Biotechnology] industry is $2.12B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARCT’s FA Score shows that 0 FA rating(s) are green whileBNTX’s FA Score has 1 green FA rating(s).

  • ARCT’s FA Score: 0 green, 5 red.
  • BNTX’s FA Score: 1 green, 4 red.
According to our system of comparison, BNTX is a better buy in the long-term than ARCT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARCT’s TA Score shows that 5 TA indicator(s) are bullish while BNTX’s TA Score has 5 bullish TA indicator(s).

  • ARCT’s TA Score: 5 bullish, 5 bearish.
  • BNTX’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, BNTX is a better buy in the short-term than ARCT.

Price Growth

ARCT (@Biotechnology) experienced а -13.89% price change this week, while BNTX (@Biotechnology) price change was -7.28% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.01%. For the same industry, the average monthly price growth was -3.31%, and the average quarterly price growth was +62.87%.

Reported Earning Dates

BNTX is expected to report earnings on Mar 10, 2026.

Industries' Descriptions

@Biotechnology (-1.01% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BNTX($23B) has a higher market cap than ARCT($178M). BNTX YTD gains are higher at: -16.112 vs. ARCT (-63.111). ARCT has higher annual earnings (EBITDA): -54.54M vs. BNTX (-72.1M). BNTX has more cash in the bank: 14B vs. ARCT (196M). ARCT has less debt than BNTX: ARCT (27M) vs BNTX (270M). BNTX has higher revenues than ARCT: BNTX (2.88B) vs ARCT (110M).
ARCTBNTXARCT / BNTX
Capitalization178M23B1%
EBITDA-54.54M-72.1M76%
Gain YTD-63.111-16.112392%
P/E RatioN/A161.76-
Revenue110M2.88B4%
Total Cash196M14B1%
Total Debt27M270M10%
FUNDAMENTALS RATINGS
ARCT vs BNTX: Fundamental Ratings
ARCT
BNTX
OUTLOOK RATING
1..100
5556
VALUATION
overvalued / fair valued / undervalued
1..100
55
Fair valued
81
Overvalued
PROFIT vs RISK RATING
1..100
10095
SMR RATING
1..100
9387
PRICE GROWTH RATING
1..100
9874
P/E GROWTH RATING
1..100
991
SEASONALITY SCORE
1..100
n/a44

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ARCT's Valuation (55) in the Pharmaceuticals Major industry is in the same range as BNTX (81) in the null industry. This means that ARCT’s stock grew similarly to BNTX’s over the last 12 months.

BNTX's Profit vs Risk Rating (95) in the null industry is in the same range as ARCT (100) in the Pharmaceuticals Major industry. This means that BNTX’s stock grew similarly to ARCT’s over the last 12 months.

BNTX's SMR Rating (87) in the null industry is in the same range as ARCT (93) in the Pharmaceuticals Major industry. This means that BNTX’s stock grew similarly to ARCT’s over the last 12 months.

BNTX's Price Growth Rating (74) in the null industry is in the same range as ARCT (98) in the Pharmaceuticals Major industry. This means that BNTX’s stock grew similarly to ARCT’s over the last 12 months.

BNTX's P/E Growth Rating (1) in the null industry is significantly better than the same rating for ARCT (99) in the Pharmaceuticals Major industry. This means that BNTX’s stock grew significantly faster than ARCT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARCTBNTX
RSI
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
86%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
81%
Momentum
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
78%
MACD
ODDS (%)
Bullish Trend 1 day ago
85%
Bearish Trend 1 day ago
72%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
79%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
78%
Advances
ODDS (%)
Bullish Trend 13 days ago
79%
Bullish Trend 11 days ago
72%
Declines
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 1 day ago
80%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
71%
Aroon
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
62%
View a ticker or compare two or three
Interact to see
Advertisement
ARCT
Daily Signal:
Gain/Loss:
BNTX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MLYNF2.27N/A
N/A
Malayan Banking Berhad
VOPKY42.44N/A
N/A
Koninklijke Vopak NV
LTGHF0.79N/A
N/A
Life Healthcare Group Holdings Ltd
KLIB142.01N/A
N/A
Killbuck Bancshares Inc.
FEERF0.02N/A
-1.50%
Freeport Resources Inc.

ARCT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARCT has been loosely correlated with ALEC. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if ARCT jumps, then ALEC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARCT
1D Price
Change %
ARCT100%
+6.10%
ALEC - ARCT
59%
Loosely correlated
+3.33%
AXON - ARCT
49%
Loosely correlated
+0.46%
NEVPF - ARCT
48%
Loosely correlated
N/A
RGNX - ARCT
43%
Loosely correlated
+8.60%
VCYT - ARCT
42%
Loosely correlated
+7.74%
More

BNTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, BNTX has been loosely correlated with MRNA. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if BNTX jumps, then MRNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BNTX
1D Price
Change %
BNTX100%
-1.42%
MRNA - BNTX
57%
Loosely correlated
+6.08%
SMMT - BNTX
52%
Loosely correlated
-1.58%
KYMR - BNTX
48%
Loosely correlated
+2.44%
TIL - BNTX
45%
Loosely correlated
+9.77%
NVAX - BNTX
44%
Loosely correlated
+4.02%
More